Biotech firms' takeover premium is on the rise

04/24/2012 | Bloomberg Businessweek

Drugmakers relying on acquisitions to replenish their pipeline are increasing bids for biotech firms, driving the average premium higher, according to Bloomberg data. For biotech takeover targets valued at greater than $500 million, the premium over 20-day average share price is 71% this year, the most in at least 12 years.

View Full Article in:

Bloomberg Businessweek

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Information Officer
Meridian Health Plan
Detroit, MI
Regulatory Analyst
Delta Dental
Alpharetta, GA
Vice President - Government Products
Health Alliance Plan
Detroit, MI
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Corporate Regulatory Lawyer EMEA (f/m)
W. L. Gore & Associates GmbH
Putzbrunn (near Munich)